

Date: 5th September, 2025

To,
Corporate Relations Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Company Code: ACCPL

Dear Sir/ Madam,

Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is to inform you that in accordance with Regulation 36(1)(b) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, the Company has sent a letter to those shareholders whose e-mail addresses are not registered with Registrar & Transfer Agent/ Depository Participants, providing the weblink of Company's website from where the Annual Report for FY 2024-25 along with Notice of the 2nd Annual General Meeting can be accessed.

A copy of the letter is enclosed herewith.

You are requested to kindly take on your record.

Thanking You.

Yours truly,
For Accretion Pharmaceuticals Limited

Harshad Rathod
Director and CFO
DIN: 09108392

Encl.: as above



CIN: L21004GJ2023PLC146545

29, Xcelon Industrial park-1, Behind Intas Pharmaceuticals, Vasna-Chacharwadi, Ta-Sanand,
Dist-Ahmedabad - 382 213, Gujarat, INDIA | Mobile: +91 9714882929

Email: compliance@accretionpharma.com | Website: www.accretionpharma.com

Date: September 4, 2025

Dear Shareholder(s),

Folio No.:

Sub: Notice of the 2nd Annual General Meeting and Annual Report for FY 2024-25 of Accretion Pharmaceuticals Limited

We are pleased to inform you that the 2nd Annual General Meeting (AGM) of **ACCRETION PHARMACEUTICALS LIMITED** ("the Company") is scheduled to be held on Thursday, 25th September, 2025 at 11.00 A.M. (IST) through Video Conference (VC) / Other Audio-Visual Means (OAVM), in compliance with the various circulars issued by Ministry of Corporate Affairs ("MCA") and Securities and Exchange Board of India ("SEBI") from time to time.

In terms of Regulation 36(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, the Notice of the 2nd AGM along with the Annual Report for the financial year 2024-25 has been sent by electronic mode to Members whose e-mail addresses are registered with the Registrar & Share Transfer Agent ("RTA") or the Depository Participants ("DPs"). Based on the records available with the RTA / DPs, your e-mail id address is not registered against your demat account / folio number and hence, in accordance with Regulation 36(1)(b) SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, this letter is sent to you to provide the web-link along with the path to access the Annual Report for FY 2024-25 of Company, which is given below.

Web link : <https://accretionpharma.com/wp-content/uploads/2025/09/Annual-Reports-of-Accretion-Pharmaceuticals-Limited-For-Financial-Year-2024-2025.pdf>

Path : Investor Relations -> Annual Report -> Annual Reports of Accretion Pharmaceuticals Limited

Website
QR code



We kindly request you to update your email address with the RTA/DPs to ensure easy access to Company documents and records.

We look forward to your participation at the AGM.

For, Accretion Pharmaceuticals Limited

Sd/-

Harshad Rathod
Director and CFO
DIN: 09108392